Hayashi Hironori, Amaya Koji, Tokoro Tomokazu, Mori Kosuke, Takenaka Shunsuke, Sugimoto Yuya, Kitano Yuto, Kurata Toru, Kawai Shunsuke, Hirose Atsushi, Tsukada Tomoya, Kaji Masahide, Shimizu Koichi, Maeda Kiichi
Department of Surgery, Toyama Prefectural Central Hospital, Toyama 930-8550, Japan.
Department of Surgery, Kaga Medical Center, Kaga, Ishikawa 922-8522, Japan.
Mol Clin Oncol. 2021 Sep;15(3):173. doi: 10.3892/mco.2021.2335. Epub 2021 Jun 29.
Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the clinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [HoM(+)] and without a history of other primary malignancies [HoM(-)]. Incidental indications during malignancy follow-up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease-free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(-) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324-4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease-free survival.
有其他原发性恶性肿瘤病史的胰腺导管腺癌（PDAC）患者的相关记录并不完善。因此，本研究旨在评估有或无其他原发性恶性肿瘤病史的PDAC患者的临床病理特征。对102例接受手术治疗的PDAC患者进行回顾性分析，这些患者有或无其他原发性恶性肿瘤病史。共有25例患者（24.5%）有其他原发性恶性肿瘤病史（年龄，有其他原发性恶性肿瘤病史者与无该病史者分别为74.2岁和68.9岁；P=0.005），且有其他原发性恶性肿瘤病史组[HoM(+)]和无其他原发性恶性肿瘤病史组[HoM(-)]之间的就诊原因存在显著差异（P<0.001）。在恶性肿瘤随访期间的偶然发现是HoM(+)组诊断PDAC最常见的原因。相反，两组之间的可切除性（P=0.645）、完整切除率（P=0.774）和最终分期（P=0.474）无显著差异。两组之间的无病生存期也无显著差异（P=0.184）。然而，HoM(+)组的总生存期明显低于HoM(-)组（P=0.003）。其他原发性恶性肿瘤病史也是总生存期较差的独立预测因素（风险比，2.416；95%置信区间，1.324 - 4.406；P=0.004）。总之，有其他原发性恶性肿瘤病史的PDAC患者的总生存期明显低于无该病史的患者，尽管无病生存期无差异。
